¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"endocrine cell cluster"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® cell-mediated immunity ÇÑ±Û ¼¼Æ÷¸Å°³¸é¿ª
¼³¸í   
  ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£Çϴ ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â Æ¯ÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù.
  
  ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº Æ¯Á¤ÇÑ ¹°Áú¿¡ °ü°èÇϴ ¸é¿ªÀÌ ¾Æ´Ï¶ó Æ¯Á¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö Àִ ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀΠ°Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼­ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇϴ ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀǠȰµ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ Æ¯ÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö Àִ ¼¼Æ÷¸¦ »ý¼ºÇϰԠÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇϰԠÇϴ °ÍÀ» ¸»ÇÑ´Ù.
¿µ¹® nerve cell ÇÑ±Û ½Å°æ¼¼Æ÷
¼³¸í   
  ½Å°æ¼¼Æ÷´Â ¿Ã¹Ù¸¥ ½Å°æÀü´ÞÀ» À§ÇÑ °¢ ºÎºÐº°·Î ³ª´µ¾îÁ® ÀÖ´Ù. ½Å°æ¼¼Æ÷¿¡¼­´Â ÀüÇØÁ®¿À´Â ÀÚ±ØÀ» Àü±âÀûÀΠ½ÅÈ£·Î ¹Ù²î¾î º¸³»°Å³ª ¹Þ°Ô µÈ´Ù. ÀÌ·± Àü±âÀûÀΠÇö»óÀº °¢ ½Å°æ¼¼Æ÷³»¿¡ Á¸ÀçÇϴ °¢ ÀÌ¿Âä³Î(ion channel: ionÀ̶õ ³ªÆ®·ý, Ä®·ý µîÀ» ÁöĪÇϴ ¸»µé·Î½á, À̵éÀÌ ¼¼Æ÷¸·¿¡ ÀÇÇØ ³ª´µ¾îÁú ¶§ »ý±â´Â Àü¾ÐÂ÷°¡ Àü±âÀû ÀÚ±ØÀ» ÀÏÀ¸Å°°í À¯ÁöÇϴµ¥ °áÁ¤ÀûÀΠ¿ªÇÒÀ» ÇÑ´Ù)µéÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ÀÌ·ç¾îÁö°Ô µÈ´Ù.
¿µ¹® glia cell ÇÑ±Û ¾Æ±³¼¼Æ÷
¼³¸í   
  ½Å°æ¼¼Æ÷ »çÀÌ¿¡¼­ ±×¹°±¸Á¶¸¦ ÀÌ·ç¸ç À̸¦ ÁöÁöÇϴ Á¶Á÷. ½Å°æ¾Æ±³¼¼Æ÷´Â ½Å°æ¸ð¼¼Æ÷¿Í °¥¶óÁø ¾Æ±³¸ð¼¼Æ÷°¡ ´Ù½Ã ¿©·¯ ÇüÅ·ΠºÐÈ­-¼ºÀåÇÑ °ÍÀÌ´Ù. ³ú½ÇÀ̳ª Ã´¼öÁ߽ɰüÀÇ º®À» µ¤°í ¿øÁÖ»ó ¶Ç´Â ÀÔ¹æÇüÀ̸ç, Ãʱ⿡´Â À¯¸®¸é¿¡ ¼¶¸ð°¡ ÀÖ´Ù. ´ëÇü¼¼Æ÷´Â º°³ú½Ç¸·¼¼Æ÷´Â ¾Æ±³¼¼Æ÷¶ó°í Çϸç, ½Å°æ¼¼Æ÷³ª ½Å°æ¼¶À¯ »çÀÌ¿¡ »êÀçÇÑ´Ù. ±× ¿Ü¿¡ Èñ¼Òµ¹±â¾Æ±³¼¼Æ÷µµ Æ÷ÇԵȴÙ.
¿µ¹® reserve cell ÇÑ±Û ¿¹ºñ¼¼Æ÷
¼³¸í   
  ÀϹÝÀûÀ¸·Î »óÇÇÁ¶Á÷¿¡¼­ À̹̠ÀÖ´ø »óÇǼ¼Æ÷°¡ ¼Õ»óÀ» ¹Þ¾Æ »ç¸êÇϸ頸ŲãÁö´Â ±× ¹Ø¿¡ Àִ ¹ÌºÐÈ­¼¼Æ÷ ¿¹¸¦ µé¸é, ±â°üÁö ³»Ç¥¸éÀ» µ¤´Â ÁßÃþ ¿øÁÖ »óÇÇÀÇ ±âÀú¿¡ Àִ ÀÛÀº ¹ÌºÐÈ­ »óÇÇ ¼¼Æ÷.
¿µ¹® stem cell ÇÑ±Û Áٱ⼼Æ÷, °£¼¼Æ÷
¼³¸í   
  Àڱ⠺¹Á¦¸¦ ÇÏ¿© ÀÚ½ÅÀ» Á¸¼Ó½ÃŰ¸é¼­ ÇÑÆíÀ¸·Î´Â Áõ½Ä°ú ºÐÈ­¸¦ ÇÏ¿© »õ·Î¿î ¼¼Æ÷¸¦ Çü¼ºÇϴ ¼¼Æ÷·Î¼­ Á¶Ç÷Áٱ⼼Æ÷°¡ ´ëÇ¥ÀûÀÌ´Ù. Á¶Ç÷Áٱ⼼Æ÷´Â °ñ¼ö¿¡ Àִ ¼¼Æ÷·Î¼­ ¸ðµç Ç÷±¸¼¼Æ÷°¡ ¿©±â¿¡¼­ ºÐÈ­µÇ¾î ¹ß»ýÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple endocrine neoplasia
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç
  • multiple endocrine neoplasia 1
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç1Çü
  • multiple endocrine neoplasia 2
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç2Çü
  • multiple endocrine neoplasia 3
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç3Çü
  • acantholytic cell
    °¡½Ã¼¼Æ÷ºÐ¸®¼¼Æ÷
  • angioimmunoblastic T-cell lymphoma
    Ç÷°ü¸é¿ª¸ð±¸T¼¼Æ÷¸²ÇÁÁ¾
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • argentaffin cell
    ÀºÄ£È­¼¼Æ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • ethmoidal cell
    ¹úÁý»À¹úÁý
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
  • goblet cell
    ¼úÀܼ¼Æ÷
  • hair cell
    Åм¼Æ÷
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • killer cell
    »ìÇØ¼¼Æ÷
  • Kupffer's cell
    º°Å«Æ÷½Ä¼¼Æ÷, ÄíÆÛ¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
  • mesothelial cell
    ÁßÇǼ¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
  • neuroendocrine cell
    ½Å°æ³»ºÐºñ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • endocrine therapy
    ³»ºÐºñ¿ä¹ý
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • acantholytic cell
    °¡½Ã¼¼Æ÷ÇØ¸®¼¼Æ÷
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÀü´Þ¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • B cell study
    B ¼¼Æ÷°Ë»ç
  • B cell/lymphocyte
    B ¼¼Æ÷/¸²ÇÁ±¸
  • B-cell
    ºñ ¼¼Æ÷
  • C-cell
    C ¼¼Æ÷
  • CD4+ cell
    CD4+ ¼¼Æ÷
  • Cell adhesion molecules
    ¼¼Æ÷À¯ÂøºÐÀÚ
  • Chinese hamster ovary tumor cell
    Áß±¹ÇÔ½ºÅÍ ³­¼Ò¼¼Æ÷, CHO¼¼Æ÷
  • Graham cell
    ±×¶óÇÔ¼¼Æ÷
  • Granulosa cell
    °ú¸³¸·¼¼Æ÷(Î¨Ø£Ø¯á¬øà)
  • Granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç(Î¨Ø£Ø¯á¬øàðþåË)
  • H-9 cell line
    H-9 ¼¼Æ÷°è
  • HeLa cell
    Çï¶ó¼¼Æ÷.
  • HeLa cell
    Çï¶ó¼¼Æ÷
  • Heidenhain s cell
    ÇÏÀ̵§ÇÏÀμ¼Æ÷.
  • Henle s cell
    Çî·¯¼¼Æ÷.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • medullary endocrine cell
    ¼ÓÁú³»ºÐºñ¼¼Æ÷
  • pancreatic endocrine cell
    ÀÌÀÚ³»ºÐºñ¼¼Æ÷
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ¼±Á¾ ÁõÈıº(ÝÂìÆàõÒýÛ¡Ò®ÝÂù²àÍðþñøý¦ÏØ).
  • endocrine
    ³»ºÐºñ(Ò®ÝÂÝô)
  • endocrine cataract
    ³»ºÐºñ¼º¹é³»Àå
  • endocrine exophthalmos
    ³»ºÐºñ¼º¾È±¸µ¹Ãâ(Áõ).
  • endocrine fracture
    ³»ºÐºñ¼º °ñÀý(Ò®ÝÂÝôàõÍéï½).
  • endocrine gland
    ³»ºÐºñ¼±(Ò®ÝÂù²àÊ)
  • endocrine gland
    ³»ºÐºñ¼±(¡­àÍ)
  • endocrine gland
    ³»ºÐºñ»ù, ³»ºÐºñ¼±.
  • endocrine gland
    ³»ºÐºñ»ù
  • endocrine glands
    ³»ºÐºñ»ù
  • endocrine organ
    ³»ºÐºñ±â°ü(Ò®ÝÂÝôÐïί).
  • endocrine physiology
    ³»ºÐºñ»ý¸®(Ò®ÝÂÝôßæ×â)
  • endocrine system
    ³»ºÐºñ°è(¡­Í§)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Bronchiolar cell [Clara cell]
    ¼¼±â°üÁö¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐºñ¼¼Æ÷
  • Parafollicular cell [Calcitonin cell]
    ¼ÒÆ÷°ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¹æ¼¼Æ÷
  • Neurolemmal cell [Schwann`s cell]
    ½Å°æÁý¼¼Æ÷
    [¿¾ ¿ë¾î] ½Å°æÃʼ¼Æ÷
  • Alpha cell [Glucagon cell]
    ¾ËÆÄ¼¼Æ÷ [±Û·çÄ«°ï¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾ËÆÄ¼¼Æ÷
  • Dark cell [Norepinephrine cell]
    ¾îµÎ¿î¼¼Æ÷ [³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷(³ë¸£¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Supporting cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Striated muscle cell
    °¡·Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Ⱦ¹®±Ù¼¼Æ÷
  • Sensory epithelial cell
    °¨°¢»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] °¨°¢»óÇǼ¼Æ÷
  • Nodal cell
    °áÀý¼¼Æ÷
    [¿¾ ¿ë¾î] °áÀý¼¼Æ÷
  • Granule cell
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³¼¼Æ÷
  • Granular lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
  • Granulosa lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell adhesion
    ¼¼Æ÷ºÎÂø(á¬øàÜõó·)
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ(á¬øàÜõó·ÝÂí­)
  • cell affinity
    ¼¼Æ÷ģȭ(á¬øàöÑûú)
  • cell blotting
    ¼¼Æ÷(á¬øà) ºí·ÔÆÃ
  • cell cloning
    ¼¼Æ÷(á¬øà) Ŭ·Î´×
  • cell coat
    ¼¼Æ÷(á¬øà)²®Áú
  • cell cycle
    ¼¼Æ÷ÁÖ±â(á¬øàñÎÑ¢)
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(á¬øàÝÂûù)
  • cell envelope
    ¼¼Æ÷(á¬øà)½Î°³
  • cell factor
    ¼¼Æ÷ÀÎÀÚ(á¬øàì×í­)
  • cell fractionation
    ¼¼Æ÷ºÐȹȭ(á¬øàÝÂüñûù)
  • cell-free amino acid incorporating system
    ¹«¼¼Æ÷(Ùíá¬øà) ¾Æ¹Ì³ë»ê ÆíÀÔ(øºìý)¾¾½ºÅÛ
  • cell-free extract
    ¹«¼¼Æ÷ÃßÃâ¹°(Ùíá¬øàõÎõóÚª)
  • cell-free protein synthesis
    ¹«¼¼Æ÷´Ü¹éÁúÇÕ¼º(Ùíá¬øàÓ±ÛÜòõùêà÷)
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dendrite cell
    ³ª¹«°¡Áö¼¼Æ÷, ¼ö»ó¼¼Æ÷
  • differentiated cell
    ºÐÈ­¼¼Æ÷
  • diffuse large cell lymphoma
    ¹Ì¸¸¼º Å«¼¼Æ÷ÀÓÆÄÁ¾
  • ependymal cell
    ³ú½Ç¸· ¼¼Æ÷, »óÀǼ¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
  • foam cell
    Æ÷¸» ¼¼Æ÷
  • follicular cell
    ¼ÒÆ÷¼¼Æ÷, ³­Æ÷¼¼Æ÷
  • germ cell
    »ý½Ä¼¼Æ÷, ¹è¼¼Æ÷
  • giant cell
    °Å¼¼Æ÷
  • giant cell tumor
    °Å¼¼Æ÷Á¾¾ç
  • goblet cell
    ¼úÀܼ¼Æ÷, ¹è³¶¼¼Æ÷
  • granular cell myoblastoma
    °ú¸³¼¼Æ÷±Ù¸ð¼¼Æ÷Á¾
  • granulosa cell
    °ú¸³¸·¼¼Æ÷
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • islet cell
    µµ¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
DC daily census; data communication; data conversion; decrease; deep compartment; Dental Corps; deoxych...
ACC accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst...
bcr breakpoint cluster region
CD Cluster of differentiation
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
M-BCR Major breakpoint cluster region
CD cluster designation
MCR minor cluster region
MCR mutation cluster region
EO Endocrine Ophthalmopathy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acinic cell carcinoma
    ¼±¹æ ¼¼Æ÷ ¾ÏÁ¾
    1. ¼±¹æ ¼¼Æ÷, ±Ù»óÇǼ¼Æ÷°¡ Áõ½ÄÇÏ¿© Çü¼ºµÇ°í ³·Àº ¾Ç¼ºµµ¸¦ º¸ÀδÙ. 2. Ÿ¾×¼± ¾à¼º Á¾¾ç Áß 5¹øÂ°ÀÇ ¹ß»ý ºñÀ²À» °®´Â Á¾¾çÀ¸·Î 90%¿¡¼­ ÀÌÇϼ±¿¡¼­ ¹ß»ýÇÏ¸ç ¾ÇÇϼ±°ú ¼ÒŸ¾×¼±¿¡¼­µµ µå¹°°Ô ¹ß»ýÇÑ´Ù. ¿©¼º¿¡¼­ ´Ù¼Ò È£¹ßÇϰí, ¾î´À ¿¬·É¿¡¼­³ª ¹ß»ýÇϳª ÁÖ·Î 30-70´ë¿¡ °ñ°í·ç ¹ß»ýÇÑ´Ù. ¿¹Àü¿¡´Â ¾ç¼ºÀ¸·Î »ý°¢ÇÏ¿© ¼±¹æ¼¼Æ÷Á¾À̶ó ºÎ¸¥ ÀûÀÌ ÀÖÀ¸³ª ºÐ¸íÇÑ ¾Ç¼ºÀ¸·Î ¼±¾ÏÁ¾À¸·Î ºÎ¸¥´Ù. Á¾¾ç ¼¼Æ÷´Â Àå¾×¼º ¼±¹æ¼¼Æ÷¿Í À¯»çÇÏÁö¸¸ ¿©·¯ °¡Áö ´Ù¸¥ ¼¼Æ÷µéÀÌ ³ªÅ¸³ª¸ç, °³Á¦°ü ¿¹ºñ¼¼Æ÷¿¡¼­ ±â¿øÇÑ´Ù°í º»´Ù.
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç ±âÀú¼¼Æ÷¾Ï
  • adenoid basal cell carcinoma
    ¼±»ó ±âÀú¼¼Æ÷¾Ï
  • adenosquamous cell carcinoma
    ¼± ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ¼± ¾Ï°ú ÆíÆò¼¼Æ÷ ¾ÏÀÌ È¥ÀçµÇ¾î ÀÖ´Â °Í. ÀÚ±Ã°æ ³»¸· »óÇÇÀÇ ±âÀú Ãþ¿¡ ÀÖ´Â ¿¹ºñ ¼¼Æ÷¿¡¼­ ¹ß»ý. ÀÌ´Â °°Àº º´±âÀÇ ÆíÆò¼¼Æ÷ ¾Ï°ú ºñ±³ÇÏ¿© ¿¹Èİ¡ ´õ ³ª»Ú´Ù.
  • adipose cell
    Áö¹æ ¼¼Æ÷
    Áö¹æÀ» °¡Áø ¼¼Æ÷·Î¼­ ¼¼Æ÷´Â ±¸ÇüÀ» ÀÌ·ç°í, ÇÙÀº ÇÑ ÂÊÀ¸·Î Ä¡¿ìÃÄ ÀÖ´Ù.
  • adrenal medullary chromaffin cell
    ºÎ½Å ¼öÁú Å©·Ò ģȭ ¼¼Æ÷
  • adult T cell leukemia
    ¼ºÀÎ T¼¼Æ÷ ¹éÇ÷º´
    ¹ßÁõ ¿¬·ÉÀº Æò±Õ 51¼¼, ÀϺ» Kyushu, Shikoku, Kii ¹Ýµµ Áö¹æ¿¡¼­ ´Ù¹ßÇϰí ÇǺΠħÀ± ¹× °£Àå, ºñÀå, ¸²ÇÁÀý Á¾´ë¸¦ ÈçÈ÷ º¼ ¼ö Àִµ¥ ºóÇ÷Àº ¾ø´ø°¡, À־ °æµµ, °ñ¼ö¿¡ÀÇ Ä§À±Àº º¸Åë ÇöÀúÇÏÁö ¾Ê´Ù. 50% »ýÁ¸Àº 4.4°³¿ù·Î ª´Ù. ¹éÇ÷º´ ¼¼Æ÷ÀÇ Æ¯Â¡Àº ÇÙÀÌ ÀÌÇüÀÌ¸ç ºÐ¿±»ó, È­ÆÇ»ó µîÀ¸·Î Áø´Ü¿¡ »ç¿ëµÈ´Ù.
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï
  • air cell
    ÇԱ⠼¼Æ÷
  • alveolar cell carcinoma
    ÆóÆ÷ ¼¼Æ÷ ¾ÏÁ¾
  • Alzheimer's cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • Alzheimers cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • amplifying cell
    Áõ½Ä ¼¼Æ÷
  • angiotropic intravascular large cell lymphoma
    Ç÷°ü ¿µ¾ç¼º Ç÷°ü³» ´ë¼¼Æ÷ ¸²ÇÁÁ¾
  • anterior horn cell
    Àü°¢ ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
neoplastic endocrine-like syndromes Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm.
(12 Dec 1998)
diagnostic techniques, endocrine Methods and procedures for the diagnosis of diseases or dysfunction of the endocrine glands or demonstration of their physiological processes.
(12 Dec 1998)
endocrine Pertaining to internal secretions, hormonal.
Compare: exocrine.
Origin: Gr. Krinein = to separate
(18 Nov 1997)
endocrine cells of gut Cells found throughout the lining of the gastrointestinal tract that contain regulatory peptide hormones and/or biogenic amines. The substances are located in secretory granules and act in an endocrine or paracrine manner. Some of these substances are also found in neurons in the gut. There are at least 15 different types of endocrine cells of the gut. Some take up amine precursors and have been called apud cells. However, most endocrine cells of the gut apparently have endodermal rather than neuroectodermal origin, so the relationship with apud cells is not clear.
(12 Dec 1998)
endocrine disorders Disorders which involve the over-production or under-production of hormone substances from an endocrine gland. Some examples include diabetes, hypothyroidism, hyperthyroidism, hyperparathyroidism, Cushing's disease, Cushing's syndrome and acromegaly.
(27 Sep 1997)
endocrine exophthalmos Exophthalmos associated with thyroid gland disorders.
See: Graves' ophthalmopathy, Graves' orbitopathy.
(05 Mar 2000)
endocrine gland Organs or gland that secrete regulatory substances directly into the circulation and not through a duct.
Examples are pituitary, thyroid, parathyroid, adrenal glands, ovary and testis, placenta and beta cells of pancreas.
(27 Sep 1997)
endocrine gland neoplasms Tumour or cancer of the endocrine glands in general or unspecified.
(12 Dec 1998)
endocrine glands Ductless glands that secrete substances which are released directly into the circulation and which influence metabolism and other body functions.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell cycle
    ¼¼Æ÷ÁÖ±â;ºÐ¿­ÁÖ±â
  • cell division
    ¼¼Æ÷ºÐ¿­
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell lysis
    ¼¼Æ÷¿ëÇØ
  • cell membrane
    ¼¼Æ÷¸·;¿øÇüÁú¸·;=CELL WALL
  • cell sorter
    ¼¼Æ÷ ºÐº°±â
  • cell therapy
    ¼¼Æ÷¿ä¹ý(¾çÀÇ °«³­»õ³¢ÀÇ ¼¼Æ÷¸¦ ÁÖÀÔÇϴ ȸÃá¹ý ('
  • cell wall
    ¼¼Æ÷º®
  • cell-mediated immunity
    ¼¼Æ÷(¸Å°³)¼º ¸é¿ª(¼¼Æ÷¸·¿¡ ºÎÂøÇÏ´Â Ç×üÀÇ Á߻꿡 ÀÇÇÑ
  • closed-cell
    µ¶¸³±âÆ÷ÀÇ;¹ÐÆó±âÆ÷ÀÇ(¼ÒÀç´Â ÇÃ¶ó½ºÆ½µî)
  • complementary cell
    º¸Á· ¼¼Æ÷
  • condemned cell (ward)
    »çÇü¼ö °¨¹æ
  • corticopontine cell
    ÇÇÁú±³¼¼Æ÷(´ë³ú ÇÇÁú¿¡ ÀÖÀ¸¸ç ½Ã°¢ ÀÚ±ØÀ» ³ú±³¿¡ º¸³¿)
  • death cell
    »çÇü¼ö °¨¹æ(µ¶¹æ)
  • dry cell
    °ÇÀüÁö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á